BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) CEO James Passin tells Proactive that Millipore-Sigma, the contract manufacturer for its preclinical viral vaccine program, has completed the bioproduction and batch release endotoxin screening of BVX-1021, the company's vaccine for SARS-CoV.
Passin explains that BVX-1021 is being used in the partnership with Ohio State University to develop a pan-sarbecovirus vaccine.
The next step is measuring neutralizing antibody development to sarbecoviruses following immunization of study animals with BVX-1021, followed by administration of a SARS-CoV-2 vaccine – in this case with BVX-0320, the company's Covid-19 vaccine candidate.